{"id":"W3120695991","doi":"10.1097/md.0000000000023677","title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”)","year":2021,"lang":"en","type":"article","venue":"Medicine","topic":"Inflammatory Myopathies and Dermatomyositis","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals; CSL Behring; Genentech; AstraZeneca; Alexion Pharmaceuticals; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Dermatomyositis; Tolerability; Placebo; Adverse effect; Randomized controlled trial; Clinical endpoint; Internal medicine; Clinical trial; Placebo-controlled study; Surgery; Physical therapy; Double blind; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004646863,0.002086321,0.004052496,0.0004721117,0.0006716237,0.001114298,0.001307802,0.002036907,0.006026686],"category_scores_gemma":[0.001973337,0.001180516,0.001407722,0.0005608688,0.001700467,0.001050179,0.0004338608,0.003262253,0.001479438],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006303699,"about_ca_system_score_gemma":0.002258171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004730363,"about_ca_topic_score_gemma":0.001242641,"domain_scores_codex":[0.9987268,0.000707795,0.00009063067,0.0002140168,0.00009962741,0.0001611395],"domain_scores_gemma":[0.9978223,0.0005389192,0.0005356708,0.0002035141,0.0002009182,0.0006987282],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9604362,0.02491777,0.0009083093,0.0004726852,0.0004423613,0.00003424308,0.00005321166,0.0002203651,0.005005662,0.00006388322,0.0005728233,0.00687252],"study_design_scores_gemma":[0.8874279,0.110197,0.001336272,0.00001566887,0.0001468452,0.0000193481,0.00001034144,0.0001676928,0.000319336,0.00004550095,0.0003056635,0.000008440107],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9766668,0.003256972,0.001316505,0.0005680508,0.0004699497,0.01425365,0.001533569,0.0001745422,0.00175999],"genre_scores_gemma":[0.9675876,0.002448785,0.004360742,0.002045247,0.0006131376,0.0181485,0.001763824,0.00004454675,0.002987574],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006026686,"threshold_uncertainty_score":0.02457529,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01772533112619751,"score_gpt":0.3242649747962098,"score_spread":0.3065396436700123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}